Aims: Ascites is one of the major complications in advanced cirrhotic patients. Tolvaptan is a non-peptide orally available arginine vasopressin V2 receptor antagonist. We investigated and found that tolvaptan therapy improved the prognosis and predictive factor of cirrhotic patients with ascites. Methods: Overall, 99 patients with newly diagnosed ascites with cirrhosis were enrolled. No patients had intrahepatic malignancy. The patients were divided into 2 groups based on tolvaptan therapy: 86 patients treated with tolvaptan (tolvaptan-group) and 13 patients treated without tolvaptan (non-tolvaptan-group). Tolvaptan-responder was defined as body weight loss of ≥1.5 kg/week after administering tolvaptan. Results: Tolvaptan therapy was effective in 61.6% of cirrhotic patients. There was a significant difference in the overall survival (OS) between the tolvaptan-responder-group and the other groups (p < 0.001). Male (HR 5.05; p = 0.01), tolvaptan responder (HR 0.21; p = 0.02), and dosage of furosemide < 40 mg/day (HR 0.17; p = 0.01) were factors that were independently associated with the OS. The multivariate analysis revealed that C-reactive protein < 0.9 mg/dL (HR 0.07; p = 0.001), and furosemide dosage < 40 mg/day (HR 0.09; p = 0.003) were independently associated with the tolvaptan response. Conclusion: Therapeutic response to tolvaptan was associated with longer survival in cirrhosis patients complicated with ascites. These preliminary findings warrant validation and further exploration.

1.
Ginès P, Cárdenas A, Arroyo V, Rodés J: Management of cirrhosis and ascites. N Engl J Med 2004; 350: 1646–1654.
2.
Moore KP, Wong F, Gines P, Bernardi M, Ochs A, Salerno F, et al: The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 2003; 38: 258–66.
3.
Runyon BA: Historical aspects of treatment of patients with cirrhosis and ascites. Semin Liver Dis 1997; 17: 163–173.
4.
Sakaida I, Kawazoe S, Kajimura K, Saito T, Okuse C, Takaguchi K, et al: Tolvaptan for improvement of hepatic edema: a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Hepatol Res 2014; 44: 73–82.
5.
Okita K, Kawazoe S, Hasebe C, Kajimura K, Kaneko A, Okada M, et al: Dose-finding trial of tolvaptan in liver cirrhosis patients with hepatic edema: a randomized, double-blind, placebo-controlled trial. Hepatol Res 2014; 44: 83–91.
6.
Sakaida I, Terai S, Kurosaki M, Yasuda M, Okada M, Bando K, et al: Effectiveness and safety of tolvaptan in liver cirrhosis patients with edema: Interim results of post-marketing surveillance of tolvaptan in liver cirrhosis (START study). Hepatol Res 2017; 47: 1137–1146.
7.
Fukui H, Saito H, Ueno Y, Uto H, Obara K, Sakaida I, et al: Evidence-based clinical practice guidelines for liver cirrhosis 2015. J Gastroenterol 2016; 51: 629–650.
8.
Iwamoto T, Maeda M, Hisanaga T, Saeki I, Fujisawa K, Matsumoto T, et al: Predictors of the effect of tolvaptan on the prognosis of cirrhosis. Intern Med 2016; 55: 2911–2916.
9.
Ohki T, Sato K, Yamada T, Yamagami M, Ito D, Kawanishi K, et al: Efficacy of tolvaptan in patients with refractory ascites in a clinical setting. World J Hepatol 2015; 7: 1685–1693.
10.
Hiramine Y, Uojima H, Nakanishi H, Hiramatsu A, Iwamoto T, Kimura M, et al: Response criteria of tolvaptan for the treatment of hepatic edema. J Gastroenterol 2017; 53: 258–268.
11.
Kanda Y: Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant 2013; 48: 452–458.
12.
Sakaida I, Yamashita S, Kobayashi T, Komatsu M, Sakai T, Komorizono Y, et al: Efficacy and safety of a 14-day administration of tolvaptan in the treatment of patients with ascites in hepatic oedema J Int Med Res 2013; 41: 835–847.
13.
Uojima H, Kinbara T, Hidaka H, Sung JH, Ichida M, Tokoro S, et al: Close correlation between urinary sodium excretion and response to tolvaptan in liver cirrhosis patients with ascites. Hepatol Res 2017; 47:E14–E21.
14.
Hiramine Y, Uto H, Imamura Y, Hiwaki T, Kure T, Ijuin S, et al: Efficacy of vasopressin V2 receptor antagonist tolvaptan in treatment of hepatic edema. Hepatol Res 2017; 47: 542–557.
15.
Nakagawa A, Atsukawa M, Tsubota A, Kondo C, Okubo T, Arai T, Itokawa N, Narahara Y, Iwakiri K, et al: Usefulness of portal vein pressure for predicting the effects of tolvaptan in cirrhotic patients. World J Gastroenterol 2016; 22: 5104–5113.
16.
Akiyama S, Ikeda K, Sezaki H, Fukushima T, Sorin Y, Kawamura Y, et al: Therapeutic effects of short- and intermediate-term tolvaptan administration for refractory ascites in patients with advanced liver cirrhosis. Hepatol Res 2015; 45: 1062–1070.
17.
Miyaaki H, Nakamura Y, Ichikawa T, Taura N, Miuma S, Shibata H, et al: Predictive value of the efficacy of tolvaptan in liver cirrhosis patients using free water clearance. Biomed Rep 2015; 3: 884–886.
18.
Nakanishi H, Kurosaki M, Hosokawa T, Takahashi Y, Itakura J, Suzuki S, et al: Urinary excretion of the water channel aquaporin 2 correlated with the pharmacological effect of tolvaptan in cirrhotic patients with ascites. J Gastroenterol 2016; 51: 620–627.
19.
Uemura Y, Shibata R, Takemoto K, Uchikawa T, Koyasu M, Ishikawa S, et al: Clinical benefit of tolvaptan in patients with acute decompensated heart failure and chronic kidney disease. Heart Vessels 2016; 31: 1643–1639.
20.
Imamura T, Kinugawa K, Fujino T, Inaba T, Maki H, Hatano M, et al: Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure. Circ J 2014; 78: 2240–2249.
21.
Kogiso T, Yamamoto K, Kobayashi M, Ikarashi Y, Kodama K, Taniai M, et al: Response to tolvaptan and its effect on prognosis in cirrhotic patients with ascites. Hepatol Res 2017; 47: 835–844.
22.
Jia JD, Xie W, Ding HG, Mao H, Guo H, Li Y, et al: Utility and safety of tolvaptan in cirrhotic patients with hyponatremia: a prospective cohort study. Ann Hepatol 2017; 16: 123–132.
23.
Tahara T, Mori K, Mochizuki M, Ishiyama R, Noda M, Hoshi H, et al: Tolvaptan is effective in treating patients with refractory ascites due to cirrhosis. Biomed Rep 2017; 7: 558–562.
24.
D'Amico G, Garcia-Tsao G, Pagliaro L: Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44: 217–231.
25.
Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al: Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 91–96.
26.
Sakaida I, Nakajima K, Okita K, Hori M, Izumi T, Sakurai M, et al: Can serumalbumin level affect the pharmacological action of tolvaptan in patients with liver cirrhosis? A post hoc analysis of previous clinical trials in Japan. J Gastroenterol 2015; 50: 1047–1053.
27.
Komiyama Y, Kurosaki M, Nakanishi H, Takahashi Y, Itakura J, Yasui Y, et al: Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio. PLoS One 2017; 12:e0174649.
28.
Kawaratani H, Fukui H, Moriya K, Noguchi R, Namisaki T, Uejima M, et al: Predictive parameter of tolvaptan effectiveness in cirrhotic ascites. Hepatol Res 2017; 47: 854–861.
29.
Nakai M, Ogawa K, Takeda R, Ohara M, Kawagishi N, Izumi T, et al: Increased serum C-reactive protein and decreased urinary aquaporin 2 levels are predictive of the efficacy of tolvaptan in patients with liver cirrhosis. Hepatol Res 2018; 48:E311–E319.
30.
Iwasa M, Sugimoto R, Hara N, Mifuji-Morioka R, Takei Y: Hyponatremia observed in hepatic cirrhosis is associated with renal function, use of diuretics and survival. Jpn J Pharmacol ther 2016; 47: 21–34.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.